<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130616013690N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-04-12</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of virtual child disease management program on parents of children with coagulation factor deficiencies</public_title>
      <acronym></acronym>
      <scientific_title>The effect of virtual child disease management program on caregiver burden and social adjustment in parents of children with coagulation factor deficiencies</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51647</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Firstly, 60 parents who their child have a record in the Hemophilia Center will be selected using a table of random numbers. Then, a random allocation software will be used to create 15 blocks with a block size of four. in order to create a list of block randomization, refer to following website is done: https://www.sealedenvelope.com/simple-randomiser/v1/lists. Then, based on this generated list (BABA, ABBA, BAAB, BABA, AABB, ...), the subjects will be allocated into the intervention (B) or control (A) groups, Blinding description: In order to perform blinding, assistant researcher who collects data before and after the intervention, as well as statistician who analyzes the data, are blinded to the groups and the assignment of individuals in the groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Hemophilia A. Condition 2: Hemophilia B. Condition 3: Von Willebrand's disease.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this group, child disease management intervention focuses on all human dimensions, including physical, psychological, social and spiritual dimensions. The content will be provided to the participants through pamphlets, PowerPoint and videos (MP4) prepared with Camtasia Studio software by WhatsApp. Physical interventions focus on how hemophilia disease and its limitations in pediatric, bleeding, pain, arthropathy, and physical activities are managed. In the psychological dimension, how to coping with child’ illness, how you deal with child hemophilia, your perception to child disease, positive thinking, laughte therapy and nature therapy are done. Social interventions include disease management in society, such as how to participate in social and job activities, and how to interact between parents, child with others, and how to child to school. Spiritual interventions include hope, prayer, and communication with God. The duration of the intervention is 8 weeks. During these 8 weeks, the prepared content is uploaded on the social network ( WhatsApp) on a daily basis. Confirmation of receipt of the program is then obtained from each participant and they are asked to watch, hear or read the presented material the next day and if they have any questions, ask their questions. The program continues until the end of the eighth week. Intervention 2: Control group: This group would receive the routine care by hemophilia center and would not receive any of the interventions of the intervention group. The parents of this child come to the Hemophilia center to receive a factor or to treat the bleeding. They may be briefed at the center on how to use the factor when the child has bleeding.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Primary outcomes would be shared.

When:
Starting 6 months after publication article

To whom:
People and researchers working in academic institutions

Conditions:
Data are provided for information only.

Where to obtain:
Data is available via email rambodma@yahoo.com.

How to obtain:
Data is available via email rambodma@yahoo.com.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Masoume Rambod</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shiraz. Zand Street, Namazi Square. School of Nursing Midwifery, Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>71936–13119</zip>
        <telephone>+98 71 3677 4254</telephone>
        <email>rambodma@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Masoume Rambod</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing and Midwifery University, Namazee Sq, Zand Ave, Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7193613119</zip>
        <telephone>+98 71 3647 4258</telephone>
        <email>rambodma@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Parents with a child in the age range of 1-11 years
Parents of a child with coagulation factor deficiencies
Parents' oriented to time, person and place
Parents' living with this child in the same house
Parents' access to the Internet and social networks</inclusion_criteria>
      <agemin>1 year</agemin>
      <agemax>11 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Parental participation in a similar disease management program over the past 3 months
Parents suffering from known mental diseases such as depression, anxiety, and psychosis
The child suffering from congenital, chromosomal, neuro-muscular and systemic diseases</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>D66</hc_code>
      <hc_code>D67</hc_code>
      <hc_code>D68.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hereditary factor VIII deficiency</hc_keyword>
      <hc_keyword>Hereditary factor IX deficiency</hc_keyword>
      <hc_keyword>Von Willebrand's disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this group, child disease management intervention focuses on all human dimensions, including physical, psychological, social and spiritual dimensions. The content will be provided to the participants through pamphlets, PowerPoint and videos (MP4) prepared with Camtasia Studio software by WhatsApp. Physical interventions focus on how hemophilia disease and its limitations in pediatric, bleeding, pain, arthropathy, and physical activities are managed. In the psychological dimension, how to coping with child’ illness, how you deal with child hemophilia, your perception to child disease, positive thinking, laughte therapy and nature therapy are done. Social interventions include disease management in society, such as how to participate in social and job activities, and how to interact between parents, child with others, and how to child to school. Spiritual interventions include hope, prayer, and communication with God. The duration of the intervention is 8 weeks. During these 8 weeks, the prepared content is uploaded on the social network ( WhatsApp) on a daily basis. Confirmation of receipt of the program is then obtained from each participant and they are asked to watch, hear or read the presented material the next day and if they have any questions, ask their questions. The program continues until the end of the eighth week.</i_keyword>
      <i_keyword>Control group: This group would receive the routine care by hemophilia center and would not receive any of the interventions of the intervention group. The parents of this child come to the Hemophilia center to receive a factor or to treat the bleeding. They may be briefed at the center on how to use the factor when the child has bleeding.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Caregiver burden. Timepoint: Before and 8 weeks after the intervention. Method of measurement: The HEMOphilia associated CAregiver Burden scale (HEMOCAB).</prim_outcome>
      <prim_outcome>Parental Social adjustment. Timepoint: Before and 8 weeks after the intervention. Method of measurement: Bell’s Social Adjustment Inventory.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-16</approval_date>
        <contact_name>Ethic Committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Vice chancellor for research affairs, seven floor, Shiraz University of Medical Science, beside Helal Ahmar, Zand Ave, Shiraz, Iran Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
